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Introduction
Phenylketonuria (PKU) is a rare autosomal recessive condition 
affecting about 1 in 13 500 to 19 000 people in the United 
States.1 Phenylketonuria is diagnosed through detection of 
elevated blood phenylalanine concentration.2 If untreated, 
PKU can cause chronic intellectual, neurodevelopmental, and 
psychiatric disabilities. Excessive phenylalanine is thought to 
interfere with brain growth, myelination, and neurotransmitter 
synthesis. Most cases of PKU are detected shortly after birth by 
newborn screening. As a result, the severe signs and symptoms 
of classic PKU are rarely seen.2
Elevated phenylalanine levels are caused by a deficiency in the 
enzyme, phenylalanine hydroxylase (PAH).2 The spectrum of 
severity in untreated PKU ranges from complete enzyme defi-
ciency or classic PKU (phenylalanine concentration > 1200 µmol/L), 
moderate PKU (phenylalanine concentration = 900-1200 µmol/L), 
mild PKU (phenylalanine concentration = 600-900 µmol/L), and 
mild hyperphenylalaninemia (HPA) (phenylalanine concentra-
tion = 360-600 µmol/L).3 Although guidelines recommend life-
long treatment to a target blood phenylalanine level of 120 to 
360 µmol/L4,5 or 120 to 600 µmol/L, (van Wegberg, MacDonald 
and Ahring, 2017) therapy must be individualized to each patient.
Management of patients with HPA and PKU should be 
provided by an interdisciplinary team of nutritionists, 
psychologists, social workers, and metabolic specialists.2 
Phenylketonuria is a relatively rare disease and patients may 
require lifelong treatment. The goal of therapy is to lower 
blood phenylalanine concentrations to minimize the neuro-
cognitive and psychiatric effects of PKU.4–7 The mainstay of 
therapy is dietary restriction of phenylalanine and supplemen-
tation with phenylalanine-free medical foods to avoid nutri-
tional deficits.4–6 The medical foods are protein substitutes 
that are phenylalanine-free and fortified in tyrosine and may 
contain glycomacropeptides and other large neutral amino 
acids as the protein source.3 Adherence to the restrictive diet 
requires planning and organization, and can be challenging for 
patients.4
Sapropterin was Food and Drug Administration (FDA)–
approved on December 13, 2007, and was the first pharmaco-
logic therapy for treatment of PKU.8 It is an oral PAH cofactor 
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indicated to reduce blood phenylalanine concentrations in 
patients with HPA due to tetrahydrobiopterin (BH4)-
responsive PKU. Sapropterin is used in conjunction with a 
phenylalanine-restricted diet.9 The efficacy of sapropterin is 
based on the presence of residual PAH enzymatic activity. 
Approximately 25% to 50% of patients with PKU respond to 
sapropterin.4
Phase 3 trials for an enzyme substitution therapy for 
PKU began in 2013 and showed promise to be effective in 
any patient with PKU regardless of residual enzymatic 
activity.4 Pegvaliase, FDA-approved on May 24, 2018, acts 
as a substitute for the deficient PAH enzyme.10 Pegvaliase 
is indicated to reduce blood phenylalanine concentrations 
in adult patients with PKU who have uncontrolled blood 
phenylalanine concentrations >600 µmol/L on existing 
management.11,12
Adult patients with PKU whose phenylalanine levels are 
not appropriately managed may experience adverse neurocog-
nitive and psychiatric outcomes.7 The objective of this article is 
to review the pharmacology, pharmacokinetics, efficacy, safety, 
and place in therapy of pegvaliase injection. It will also provide 
an overview of the role of pegvaliase compared with current 
standard of care.
Data Sources
A search of MEDLINE (1946-September 1, 2018) was con-
ducted using the terms pegvaliase and phenylalanine ammonia 
lyase (PAL). The 2 terms were combined with the Boolean 
operator OR. The term pegvaliase was also searched on its 
own. All English language articles related to pharmacology, 
pharmacokinetics, efficacy, or safety of the therapy in human 
subjects were included. The references of included articles 
were searched to identify additional sources. The product dos-
sier was obtained from the manufacturer, and additional data 
were obtained from the prescribing information and 
Clinicaltrials.gov.
Data Synthesis
Pharmacology
PAH catalyzes the irreversible conversion of phenylalanine 
to tyrosine. In the absence of PAH in PKU, dietary phenyla-
lanine is unable to be converted to tyrosine and undergoes 
further processing to metabolites including L-dopa, thyrox-
ine, dopamine, noradrenaline, adrenaline, and melanin.13 
There are 2 modes of enzyme therapy through replacement 
of the PAH enzyme or substitution with another enzyme to 
degrade excess phenylalanine.12 Pegvaliase follows the latter 
category and is a pegylated PAL enzyme that converts phe-
nylalanine to ammonia and trans-cinnamic acid.8 Ammonia 
is metabolized by the liver. Trans-cinnamic acid and its final 
product, benzoic acid, are conjugated with glycine and 
excreted in the urine.13,14
Pharmacokinetics
Due to the heterogeneity of immune response in adults with 
PKU, the pharmacokinetics of pegvaliase exhibit high interpa-
tient and intrapatient variability. High antibody titers corre-
lated with higher apparent clearance. The pharmacokinetic 
parameters are summarized in Table 1.
Clinical Trials
Phase 1
Clinical trial experience with pegvaliase is summarized in Table 
2. The first study of pegvaliase in humans was a phase 1, multi-
center, open-label study in patients over the age of 18 with a 
diagnosis of classic PKU (phenylalanine concentration 
>1200 µmol/L at diagnosis) and had a history of poor dietary 
compliance (PAL-001, NCT00634660). The average baseline 
phenylalanine concentration was 1310 µmol/L, and the average 
body mass index (BMI) was 26.4 kg/m2. Twenty-five patients 
were recruited from 7 centers in the United States. Patients were 
Table 1. Summary of pharmacokinetic parameters studied.
PHARMACokInETIC PARAMETER DAIly MAInTEnAnCE DoSAgE
PEgVAlIASE 20 Mg PEgVAlIASE 40 Mg
Median Tmax 8 hours
Cmax at steady state (mean ± SD) 14.0 ± 16.3 mg/l 16.7 ± 19.5 mg/l
Apparent volume of distribution (mean ± SD) 26.4 ± 64.8 l 22.2 ± 19.7 l
Apparent clearance at steady state (mean ± SD) 0.39 ± 0.87 l/h 1.25 ± 2.46 l/h
Half-life (mean ± SD) 47 ± 42 hours 60 ± 45 hours
Steady state plasma concentrations during maintenance treatment (mean ± SD) 11.2 ± 9.0 mg/l 10.4 ± 12.7 mg/l
Metabolism Catabolic pathways, degraded into small peptides 
and amino acids
Abbreviations: Cmax, peak concentration; Tmax, time to peak concentration.
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excluded if they had renal or hepatic dysfunction, had pregnancy 
or potential pregnancy, or used nicotine, drugs of abuse, or any 
investigational products in the 30 days prior to screening.15
Twenty-five patients were assigned to 1 of 5 dosing groups 
in which they received a single subcutaneous injection of peg-
valiase on day 1: 0.001, 0.003, 0.10, 0.03, and 0.100 mg/kg. 
Patients were followed up for 42 days. In the patients who 
received the 0.1 mg/kg dose, pegvaliase significantly reduced 
phenylalanine concentrations (1113 to 575 mmol/L, mean 
reduction of 48.3%) on day 6. Phenylalanine concentrations 
increased from day 7 to day 21 and remained relatively consist-
ent through the end of the study.15
Phase 2
The optimal dosing regimens were explored in 3 phase 2 stud-
ies of pegvaliase. PAL-002 (NCT00925054) was an open-
label, multicenter study of 40 adults with PKU. Patients entered 
an 8-week induction phase of various fixed and weight-based 
doses of pegvaliase administered weekly, followed by an 8-week 
titration phase during which increasing doses of pegvaliase 
were administered weekly with the goal of achieving reduced 
blood phenylalanine concentrations. The doses ranged from 
0.001 to 0.1 mg/kg throughout the study. These doses were not 
sufficient to lower phenylalanine concentrations.
Table 2. Summary of trials of pegvaliase for the treatment of PkU in adults.
PHASE IDEnTIFIER DESIgn DURATIon DoSIng n RESUlTS
1 nCT00634660 
(PAl-001)
ol, single dose 42 days 0.001, 0.003, 0.10, 0.03, 
and 0.100 mg/kg
25 48.3% reduction in Phe from day 4 to 7 
in the highest dosing group
2 nCT00925054 
(PAl-002)
ol, multiple dose 
with induction and 
titration phases
16 weeks 0.001-0.1 mg/kg given 5 d/
wk
40 no significant changes in Phe
5% (2 patients) discontinued due to 
AEs
2 nCT01212744 
(PAl-004)
ol, multiple dose 13 weeks 0.06-0.8 mg/kg/d given 
5 d/wk
16 no significant changes in Phe
6.25% (1 patient) discontinued due to 
AEs
2 nCT01560286 
(165-205)
ol, multiple dose 
with induction, 
titration, and 
maintenance 
phases
24 weeks 2.5 mg weekly × 
4-8 weeks, then increased 
to a maximum of 75 mg 
daily
24 46% reached maintenance dose
56% reduction in Phe
54% did not reach maintenance dose
8.33% (2 patients) discontinued due to 
AEs
2 nCT00924703 
(PAl-003)
ol, multiple dose 
extension study
Extended 
follow-up of 
phase 2 
studies to 
264 weeks
Continued or increased 
from parent studies, up to 
375 mg/wk given up to 7 d/
wk
68a 58.9% reduction in Phe at 48 weeks
72.3% reduction in Phe at 120 weeks
5.9% (4 patients) discontinued due to 
AEs
3 nCT01819727 
(PRISM-1)
ol, randomized 
multiple dose with 
induction, titration, 
and maintenance 
phases
24 months 2.5 mg daily titrated to 
either 20 or 40 mg daily
261 51.1% reduction in Phe at 12 months
68.7% reduction in Phe at 24 months
Improvement in mood and inattention 
scores
11% (29 patients) discontinued due to 
AEs
3 nCT01889862 
(PRISM-2)
PRISM-1 extension 
studyb
 
  Part 1 ol continuation of 
PRISM-1
20 or 40 mg daily Data not published
  Part 2 R discontinuation 
study
8 weeks 20 mg daily, 40 mg daily, 
or placebo
86 no change in Phe in the groups that 
maintained doses
62.6% increase in Phe in placebo 
20 mg group
56.4% increase in Phe in placebo 
40 mg group
no patients discontinued due to AEs
  Part 3 ol, PD, Pk 20 or 40 mg daily Data not published
  Part 4 ol extension ongoing 5-60 mg daily ongoing
Abbreviations: AEs, adverse events; ol, open label; PD, pharmacodynamics; Phe, phenylalanine; Pk, pharmacokinetic; PkU, phenylketonuria; R, 
randomized.
aPatients from the other phase 2 studies.
b12 patients from the phase 2 studies, but their data are not reported.
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PAL-004 (NCT01212744) was an open-label, multicenter 
study of 16 adults with PKU. Patients were given doses of peg-
valiase 5 d/wk which ranged from 0.06 to 0.8 mg/kg through-
out the 13 weeks of the study. Similar to PAL-002, the doses 
studied resulted in inadequate control of blood phenylalanine 
levels. All patients in both studies experienced at least 1 adverse 
event (AE). The regimens used in PAL-002 were generally 
well tolerated, but the higher doses in PAL-004 were associ-
ated with more frequent hypersensitivity reactions (which 
included arthralgia, arthritis, eye inflammation, eye irritation, 
eye pain, joint stiffness, joint swelling, pyrexia, vision blurred, 
and polyarthritis) and the need for dose reduction.16
Based on observations made in PAL-002 and PAL-004, a 
third phase 2 study, 165-205 (NCT01560286), was conducted. 
This study was an open-label, multicenter study that was 
24 weeks in duration. Patients were eligible if they had a blood 
phenylalanine concentration of ⩾600 µmol/L at screening and 
an average concentration of ⩾600 µmol/L in the 6 months prior 
to the screening, and no prior treatment with sapropterin in the 
4 months prior to screening. Patients who were pregnant, plan-
ning to become pregnant, or breastfeeding were excluded. 
Patients entered a 4- to 8-week induction phase of 2.5 mg/wk. 
Afterward, the dose and frequency could be increased over a 
minimum of 4 weeks to attain a blood phenylalanine concentra-
tion of ⩽600 µmol/L. The authors defined the “maintenance 
dose” as the regimen that resulted in target concentrations for 
4 weeks without the need for dose adjustments. Once the main-
tenance dose was determined, patients entered the next phase. 
In the maintenance phase, the maintenance dose was continued 
but could still be adjusted for safety or to maintain concentra-
tions below 600 µmol/L. The maximum dose in the mainte-
nance phase was 75 mg/d given 5 d/wk. However, the protocol 
was updated to change the maximum frequency to 7 d/wk. 
Patients experiencing severe hypersensitivity adverse events 
(HAEs) had their dosing interrupted or adjusted and restarted 
at the same or a lower dose. Another protocol change allowed 
patients with treatment-related acute systemic hypersensitivity 
events to permanently discontinue the study drug. The investi-
gators used a modified intention-to-treat analysis consisting of 
participants who received at least 1 dose of the study drug and 
had at least 1 post-treatment blood phenylalanine level.17
Twenty-four patients enrolled in the study, with 11 patients 
achieving maintenance dose in the first 24 weeks (group A) and 
13 patients not achieving maintenance dose within 24 weeks 
(group B). Patients had a mean age of approximately 29 years, 
and baseline blood phenylalanine concentrations were similar 
in both groups (1134.8 µmol/L in group A vs 1197.5 µmol/L in 
group B). However, group A was comprised mostly of women 
with a mean weight of 64.6 kg, whereas group B was mostly 
men with a mean weight of 86.4 kg. Baseline total protein 
intake and dietary phenylalanine intake were higher in group 
B. Mean doses of pegvaliase in the 24-week study were 64.7 mg 
in group A and 89.4 mg in group B. The group A patients’ 
mean blood phenylalanine concentration reached <600 µmol/L 
by week 11 of the study. The mean reduction from baseline was 
627 ± 432 µmol/L (56% ± 36% reduction). Furthermore, all 
patients in group A reached a blood phenylalanine concentra-
tion target of <120 µmol/L during the 24-week study. Group 
A had lower anti-drug antibody responses, which was likely 
associated with less immune-related clearance compared with 
patients in group B with higher anti-drug antibody responses. 
Ten of the 13 patients in group B continued on to the exten-
sion study, during which they achieved a blood phenylalanine 
concentration of ⩽600 µmol/L by week 48.17
Patients in the 3 phase 2 dosing finding studies (will be 
referred to hereon in as “parent studies”) were invited to continue 
on in an extension study (PAL-003, NCT00924703) if they were 
willing to continue stable protein intake. Patients taking any 
other injectable drug containing polyethylene glycol (PEG) and 
patients with a history of systemic hypersensitivity events to a 
PEG-containing product were excluded. However, patients with 
a previous reaction to pegvaliase could be eligible for the study on 
a case by case basis. Doses for individuals were either continued 
from the parent study or increased and were adjusted throughout 
the study to attain or maintain phenylalanine concentrations 
between 60 and 600 µmol/L. In addition, doses could be adjusted 
to manage AEs. Initially, dosing ranged from 2.5 to 375 mg/wk 
or 0.001 to 5 mg/kg/wk, but a protocol changed limited weekly 
dosing to 375 mg/wk. The authors used a modified intention-to-
treat analysis for efficacy which included all patients who received 
1 dose of pegvaliase and had at least 1 phenylalanine concentra-
tion measurement taken after treatment.17
Sixty-eight of the 80 participants in the parent studies enrolled 
in the extension study. The baseline phenylalanine concentration 
was 1022.4 µmol/L. The mean daily dose of pegvaliase in the par-
ent studies was 5.3 mg/d (SD = 6.8 mg/d), and this increased to 
26.2 mg/d (SD = 17.9 mg/d) in the extension study. Doses 
remained relatively stable from week 48 to week 120 of the study. 
The average duration of treatment in all of the phase 2 studies 
was approximately 3.4 years. Mean phenylalanine concentrations 
decreased throughout the study by more than half (58.9%) at 
week 48 of treatment and by 72% at week 120 (1022.4 µmol/L at 
baseline, 541.6 µmol/L at week 48, and 372 µmol/L at week 
120).17
Approximately one-third of patients (36.8%) had their peg-
valiase dosing reduced or held during the study. A small number 
of patients (n = 4, 5.9%) discontinued the study due to AEs. All 
4 patients reported resolution of the AEs after discontinuing 
treatment. Hypersensitivity adverse events were highest during 
early treatment in phase 2 studies and correlated with the tim-
ing of highest IgM, PEG IgM, and PEG IgG antibodies.17
Phase 3
Pegvaliase was evaluated in a phase 3 study, PRISM-1 
(NCT01819727). In this multicenter, open-label study, patients 
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naïve to pegvaliase were randomized to receive 1 of 2 regimens 
of pegvaliase. Patients with a blood phenylalanine concentra-
tion of 600 µmol/L or higher for at least 6 months prior to the 
study were eligible. It is unclear if allocation to treatment 
groups was concealed. Both groups received 2.5 mg once per 
week of pegvaliase subcutaneously for 4 weeks during the 
induction period. Dosing and frequency were increased gradu-
ally to either 20 mg/d or to 40 mg/d. Titration was performed 
over a period of 5 to 30 weeks. The schedule was described for 
the 20 mg/d group: 2.5 mg twice weekly, 10 mg weekly, 10 mg 
twice weekly, 10 mg 4 times weekly, 10 mg daily, and then 
20 mg daily. Doses were continued in the maintenance phase, 
which ranged from 24 to 36 weeks in duration. Phenylalanine 
levels, safety, immunogenicity, and neuropsychiatric symptoms 
were assessed by trained study staff at each site using tools vali-
dated for use in PKU.18
PRISM-1 included 261 patients: 131 in the 20 mg/d group 
and 130 in the 40 mg/d group. Patients had a mean age of 
approximately 30 years at baseline and were mostly white, and 
approximately half of them were women. Mean phenylalanine 
levels at baseline were 1232.7 µmol/L. The mean number of 
weeks to reach maintenance doses was 11.5 and 14 in the 
20 mg/d and 40 mg/d groups, respectively.18
Mean phenylalanine concentrations decreased by 51.1% 
from baseline to 564.5 µmol/L at 12 months of follow-up, and 
by 68.7% from baseline to 311.4 µmol/L at 24 months of fol-
low-up. Inattention and mood scores improved while on treat-
ment with pegvaliase and correlated with a decrease in 
phenylalanine levels. Similar to previous studies, all patients 
experienced at least 1 AE. However, in this study, 99% of events 
were mild to moderate in nature, and 96% resolved without 
dose reduction or interruption. This represents an improve-
ment in the safety profile compared with previous regimens 
studied. The most common AEs were arthralgia (70.5%), 
injection site reactions (62.1%), injection site erythema (47.9%), 
and headache (47.1%). Of the AEs leading to discontinuation, 
2.7% were anaphylaxis, 2.7% were arthralgia, 1.1% were injec-
tion site reactions, and 0.8% were generalized rash. Twelve 
patients (4.6%) experienced 1 or more acute systemic HAEs 
which were independently adjudicated by an allergist/immu-
nologist. The median time after pegvaliase administration to 
acute systemic HAE was 1.8 minutes, and all occurred within 
the first 50 days of dosing and were resolved quickly.18
Patients enrolled in PRISM-1 could continue to PRISM-2 
(NCT01889862), a study to evaluate the safety and efficacy of 
long-term treatment. Patients reaching maintenance dosing in 
PRISM-1 entered part 1 of PRISM-2, and continued their 
assigned doses, either 20 mg or 40 mg daily. Part 2 was a rand-
omized, double-blinded, placebo-controlled discontinuation 
study which will be described below. Part 3 was an open-label 
pharmacodynamics and pharmacokinetic study, and part 4 is an 
open-label extension study which is ongoing. Patients who did 
not reach maintenance dosing in PRISM-1 could enter directly 
in to part 4 of PRISM-2, in which the open-label dosing 
ranges from 5 to 60 mg daily.18
Eighty-six patients who received pegvaliase in PRISM-2 
part 1 enrolled in the double-blinded PRISM-2 part 2 discon-
tinuation trial. An additional 9 patients were enrolled but were 
not included in the efficacy analysis. Patients were randomized 
via concealed allocation to receive either their current pegvali-
ase dose (either 20 or 40 mg/d) or matched placebo containing 
either 20 mg or 40 mg of Dextran 40 (22% Dextran 40). The 
study drugs were self-administered daily for 8 weeks, rotating 
subcutaneous injection sites.19
The pooled active pegvaliase group phenylalanine concen-
trations remained stable from baseline to week 8 (503.9-
559 µmol/L), while levels in both placebo groups increased 
(563.9-1509 µmol/L in the placebo 20 mg group and 508.2-
1164.4 µmol/L in the placebo 40 mg group). However, no sig-
nificant changes in mood or inattention were observed, perhaps 
due to the short duration of the trial or to the tools used to 
measure these symptoms in the trial.19 Patients in PRISM-1 
demonstrated improvements in attention deficit hyperactivity 
disorder (ADHD) scores at 3 months of treatment.16
Overall, clinical trial experience from phase 1 to phase 3 
suggests substantial reductions in blood phenylalanine concen-
trations and improvement in inattention and mood symptoms 
with the use of pegvaliase. However, these benefits must be 
weighed against the risk of common and sometimes serious 
AEs.
Dosing and Administration
The package insert for Palynziq recommends to obtain base-
line blood phenylalanine concentrations prior to treatment ini-
tiation.11 The induction dosage for pegvaliase is 2.5 mg 
subcutaneously once weekly for 4 weeks under the supervision 
of a health care provider. The dosage should be titrated based 
on tolerability over at least 5 weeks to achieve a dosage of 20 mg 
subcutaneously once daily. Therapeutic response may not be 
achieved until the patient is titrated to an effective mainte-
nance dose.
During treatment, patient tolerability, blood phenylala-
nine concentrations, dietary protein, and phenylalanine 
intake should be monitored. Studies in adult PKU patients 
have shown a variation in phenylalanine levels can be 
observed without any change in treatment.20 In clinical trials, 
the response to sapropterin treatment was defined as a 30% 
reduction in blood phenylalanine concentration from base-
line.21 In contrast, therapeutic response with pegvaliase was 
based on a 20% reduction in blood phenylalanine concentra-
tion from baseline or a blood phenylalanine concentration 
⩽600 µmol/L after 24 weeks. If not achieved, increasing the 
pegvaliase dose to a maximum dosage of 40 mg subcutane-
ously once daily can be considered. If therapeutic response 
has not been achieved after 16 weeks on the maximum dos-
age, discontinuation of pegvaliase is recommended. If 
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patients experience blood phenylalanine concentrations 
<30 µmol/L during titration and maintenance, the dosage of 
pegvaliase may be reduced or the dietary protein and pheny-
lalanine intake may be modified.11
For hypersensitivity reactions, premedication can be consid-
ered with an H1-receptor antagonist, H2-receptor antagonist, 
and/or antipyretic prior to administration based on tolerability. 
Patients should be observed during and for at least 60 minutes 
after receiving pegvaliase injection. Patients should also be 
trained on recognition of signs and symptoms of anaphylaxis, 
how to administer injectable epinephrine, and how to seek 
emergency care, if needed. If the decision is made to readmin-
ister pegvaliase after an episode of anaphylaxis, the subsequent 
dose should be administered under the supervision of a health 
care provider after titrating based on patient tolerability and 
therapeutic response.11
Due to the risks of anaphylaxis, pegvaliase is only available 
through a Risk Evaluation and Mitigation Strategies (REMS) 
program which includes prescriber and pharmacy certification 
requirements and patient educational enrollment. In clinical 
trials, most patients developed anti-PEG IgM and IgG anti-
bodies after treatment. The clinical effects of concomitant 
treatment with other pegylated products are unknown. 
Therefore, if patients are treated in combination with other 
pegylated products, further monitoring for hypersensitivity 
reactions and anaphylaxis is recommended.11
Relevance to Patient Care and Clinical Practice
The risk of adverse outcomes in PKU is related to disease sever-
ity, blood phenylalanine concentration, and adherence to treat-
ment.4 The assessment of blood phenylalanine concentrations 
may also be indicative of patient adherence to therapy.22 Poor 
adherence can manifest as failure to take medical foods or pre-
scribed medications, and missing regular clinic appointments or 
blood phenylalanine testing.23 A presentation released by 
BioMarin Pharmaceuticals suggests there are 125 PKU clinics 
in the United States currently managing patients through die-
tary counseling and/or sapropterin.24 A study of 45 PKU clinics 
showed that non-adherence to clinic-recommended target phe-
nylalanine concentrations increased with age. Most adults had 
blood phenylalanine concentrations >360 µmol/L with 15% of 
patients aged 18 to 29 years and 20% of patients aged 30+ years 
reported to have concentrations >1200 µmol/L.23 Given that 
PKU can cause neurocognitive and psychiatric symptoms, there 
may be an unmet need for additional therapeutic approaches in 
adults with uncontrolled disease.
Dietary treatment consists of dietary restriction of phenyla-
lanine, phenylalanine-free protein substitutes (l-amino acid 
mixtures), and modified low-protein foods.4,6 Patients with 
residual enzymatic activity of PAH may respond to sapropterin 
which increases metabolism of phenylalanine to tyrosine. 
Safety and efficacy of sapropterin have been established in 
pediatric patients as young as 1 month of age.21 Prior to routine 
treatment with sapropterin, a test should be conducted to 
determine if the patient is sapropterin-responsive, defined as a 
rapid decline in phenylalanine or increase in phenylalanine tol-
erance. Sapropterin can provide better phenylalanine control 
and increase dietary phenylalanine tolerance.25 Clinical guide-
lines have recently been updated on to address the role of peg-
valiase in management of PKU. The goal of pegvaliase 
treatment is to provide maintenance of blood phenylalanine 
concentrations while normalizing diet. Pegvaliase can be con-
sidered for all adult patients with PKU who can adhere to 
therapy, including requirement for monitoring of AEs.26 No 
head-to-head trials were conducted comparing the safety and 
efficacy of sapropterin with pegvaliase. Given patients in the 
clinical trials were unable to continue sapropterin in the peg-
valiase trials, it is unclear whether the combination is statisti-
cally and clinically more beneficial than either treatment alone.
Although the package insert for pegvaliase does not specify 
use to be in conjunction with a phenylalanine-restricted diet, it is 
indicated in patients with uncontrolled blood phenylalanine 
concentrations “on existing management”11 which can be 
inferred as guideline-recommended dietary therapy and/or sap-
ropterin pharmacotherapy. Furthermore, in pegvaliase clinical 
trials, patients were stable in protein intake and in many instances 
received counseling from a dietician.15–19 However, while 
Thomas et al observed stable total dietary protein intake, there 
was a decrease in medical food protein (from 26.3 to 18.4 g/d) 
and an increase in dietary phenylalanine intake (from 1700.2 to 
2679.7 mg/d). This shift may indicate a decreased need for med-
ical food.18 Efficacy of pegvaliase without dietary therapy was 
not assessed in clinical trials. Due to the potential shifts in dos-
ing from changing dietary protein and phenylalanine intake, 
continuation of nutritional and blood phenylalanine monitoring 
is warranted in patients treated with pegvaliase.11,26
Given only 25% to 50% of patients with PKU respond to 
sapropterin,3 the availability of additional pharmacologic 
options is necessary to improve the quality of life in patients 
with uncontrolled PKU. In 2015, the National PKU Alliance 
conducted a survey of adults and children with PKU in the 
United States. The survey confirmed that dietary therapy is the 
mainstay of clinical treatment. Approximately 6% of survey 
respondents stated they were not treating PKU with medical 
foods or pharmacotherapy. Most survey respondents (91%) 
stated the importance of development of new products for 
PKU. Respondents generally preferred oral therapy over inject-
able therapy, and home injections over injections, at a medical 
facility.27 Pegvaliase is a novel enzyme substitution therapy 
which can be used in patients with more severe disease and in 
part meets the needs of the PKU community. The subcutane-
ous prefilled syringe can be self-administered if patients dem-
onstrate adequate competency.11 Although an oral pegylated 
PAL formulation has been investigated in animal studies,28 
similar trials have not been conducted in humans. It is recom-
mended that multidisciplinary teams continue involvement in 
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care of patients with PKU, including monitoring therapeutic 
response, adverse effects, and medication adherence.
Cost
As of June 2018, pegvaliase has been launched. For cost consid-
erations, the average wholesale price (AWP) for pegvaliase-
pqpz prefilled syringes are US$585.60 which includes 3 
strengths: 2.5 mg/0.5 mL, 10 mg/0.5 mL, and 20 mg/mL, 
whereas the AWP of sapropterin 100 and 500 mg tablets are 
US$44.28 and US$221.40 per tablet, respectively.29,30 Using 
these AWP cost figures, the 30-day cost for a 70 kg patient at 
the maximum recommended sapropterin dose (20 mg/kg once 
daily) is US$5314 and at the maximum recommended pegvali-
ase-pqpz dose (40 mg once daily) is US$35 136. BioMarin 
Pharmaceuticals predicts the average annual net cost of therapy 
for a typical patient to be approximately US$192 000 per year 
based on an average of 1.5 units per patient at maintenance 
dosing.24 Dietary treatments used in conjunction with cur-
rently available pharmacotherapy pose an additional cost bur-
den to patients and payers.
Conclusions
Patient characteristics and preferences should be considered to 
help guide treatment of PKU. Pegvaliase reduces blood pheny-
lalanine concentrations independent of PAH activity compared 
with previously available therapeutic alternatives.4 In pivotal 
phase 3 clinical studies, treatment with pegvaliase was associ-
ated with overall safety and statistically significant improve-
ments in blood phenylalanine concentrations.18,19 Patients also 
had sustained reductions in blood phenylalanine concentra-
tions that reached guideline-recommended levels. However, 
due to risks of anaphylaxis, pegvaliase is only available through 
a restricted program under REMS.11 The injectable route of 
administration, potential risks, and factors related to insurance 
coverage may limit the use of pegvaliase. At the present time, 
pegvaliase is only FDA-approved for use in adults who have 
uncontrolled blood phenylalanine concentrations 
>600 µmol/L.11 Clinical guidelines have been updated to 
address the role of pegvaliase in management of PKU.26 Given 
the high cost, therapy may be a viable option for patients who 
have failed existing management strategies due to inadequate 
response or desire for dietary relaxation. Further research 
should be conducted to evaluate the safety and efficacy in 
younger patients, those with milder forms of PKU, in combina-
tion with sapropterin, and with limited dietary therapy.
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